Please login to the form below

Not currently logged in
Email:
Password:

cemiplimab

This page shows the latest cemiplimab news and features for those working in and with pharma, biotech and healthcare.

Orphan drugs dominate FDA's record-breaking year

Orphan drugs dominate FDA's record-breaking year

myasthenic syndrome (LEMS), Novimmune’s Gamifant (emapalumab) for primary hemophagocytic lymphohistiocytosis (HLH), Regeneron/Sanofi’s Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC), and SIGA Technologies’ TPOXX (tecovirimat)

Latest news

  • As France protests, Sanofi takes axe to 670 jobs As France protests, Sanofi takes axe to 670 jobs

    dermatitis therapy Dupixent (dupilumab), checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi(caplacizumab) for acquired thrombotic thrombocytopenic purpura.

  • Dupixent helps put Sanofi back on growth track Dupixent helps put Sanofi back on growth track

    Brandicourt is also hoping for new sales momentum from two new product approvals – checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura

  • Immuno-oncology at ASCO: survival data, combinations and new indications Immuno-oncology at ASCO: survival data, combinations and new indications

    Finally, PD-1 latecomers Sanofi and Regeneron will share the first results from an early-stage trial of their candidate cemiplimab in NSCLC at ASCO, as a monotherapy in patients who

  • Regeneron’s Dupixent and Praluent falls short Regeneron’s Dupixent and Praluent falls short

    Schleifer spent a sizeable portion of the conference call talking up Regeneron’s emerging position in immuno-oncology, currently led by Sanofi-partnered PD-1 inhibitor cemiplimab, which is due for ... The company has chosen a first indication for

  • Sanofi’s latecomer PD-1 gets date for FDA verdict Sanofi’s latecomer PD-1 gets date for FDA verdict

    Regeneron-partnered cemiplimab is the first of the new wave of checkpoint inhibitors to be filed for CSCC, and also picked up a breakthrough designation from the FDA last September. ... Sanofi has three trials of cemiplimab either ongoing or planned in

More from news
Approximately 3 fully matching, plus 7 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics